Determinants of Vascular Function in Patients With Chronic Gout

Journal of Clinical Hypertension

Volumn 13, Issue 3, 2011, Pages 178-188

  Brook, Robert D ^a   Yalavarthi, Srilakshmi ^a   Myles, James D ^b   Khalatbari, Shokoufeh ^b   Hench, Rita ^a   Lustig, Susan ^a,b   Marder, Wendy ^a   Neidert, Adam ^a   Kaplan, Mariana J ^a  

^a Department of Internal Medicine   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; APOPTOSIS; ARTERY BLOOD FLOW; ARTERY COMPLIANCE; ARTERY DILATATION; ARTICLE; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GOUT; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; VASCULAR SMOOTH MUSCLE;

ADULT; APOPTOSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR SYSTEM; CASE-CONTROL STUDIES; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GOUT; HEALTH STATUS INDICATORS; HUMANS; HYPERURICEMIA; MALE; MICROVESSELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 79952142762     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00406.x     Document Type: Article

References (60)

1. Baker JF, Krishnan E, Chen L, et al. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118(8):816-826.
2. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041-1049.
3. Wen CP, David Cheng TY, Chan HT, et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis. 2010;56(2):273-288.
4. Iribarren C, Folsom AR, Eckfeldt JH, et al. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis risk in Communities. Ann Epidemiol. 1996;6(4):331-340.
5. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170-180.
6. Alderman MH. Podagra, uric acid, and cardiovascular disease. Circulation. 2007;116(8):880-883.
7. Boogaerts MA, Hammerschmidt DE, Roelant C, et al. Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury. Thromb Haemost. 1983;50(2):576-580.
8. Chapman PT, Yarwood H, Harrison AA, et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum. 1997;40(5):955-965.
9. Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553-3562.
10. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111-1115.
11. Wong M, Toh L, Wilson A, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum. 2003;48(1):81-89.
12. Maki-Petaja KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation. 2006;114(11):1185-1192.
13. Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford). 2006;45(3):283-286.
14. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895-900.
15. Brook RD, Brook JR, Urch B, et al. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. Circulation. 2002;105(13):1534-1536.
16. Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004;103(10):3677-3683.
17. Denny MF, Thacker S, Mehta H, et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. 2007;110(8):2907-2915.
18. Van Doornum S, McColl G, Jenkins A, et al. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum. 2003;48(1):72-80.
19. Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract. 2005;59(11):1276-1282.
20. Shah A, Keenan RT. Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep. 2010;12(2):118-124.
21. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104-1110.
22. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900.
23. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83, 683 Austrian men. Clin Chem. 2008;54(2):273-284.
24. Corry DB, Tuck ML. Uric acid and the vasculature. Curr Hypertens Rep. 2006;8(2):116-119.
25. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183-1190.
26. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7-13.
27. Tan TY, Lu CH, Lin TK, et al. Factors associated with gender difference in the intima-media thickness of the common carotid artery. Clin Radiol. 2009;64(11):1097-1103.
28. Neogi T, Ellison RC, Hunt S, et al. Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart Study. J Rheumatol. 2009;36(2):378-384.
29. Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41(3):237-242.
30. De Muckadell OB, Gyntelberg F. Occurrence of gout in Copenhagen males aged 40-59. Int J Epidemiol. 1976;5(2):153-158.
31. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25(1):39-42.
32. Kato M, Hisatome I, Tomikura Y, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol. 2005;96(11):1576-1578.
33. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924-932.
34. Nakagawa T, Tuttle KR, Short RA, et al. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract. 2005;1(2):80-86.
35. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105(22):2619-2624.
36. Eskurza I, Kahn ZD, Seals DR. Xanthine oxidase does not contribute to impaired peripheral conduit artery endothelium-dependent dilatation with ageing. J Physiol. 2006, 571(Pt 3):661-668.
37. O'Driscoll JG, Green DJ, Rankin JM, et al. Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects. Clin Exp Pharmacol Physiol. 1999;26(10):779-783.
38. Butler R, Morris AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35(3):746-751.
39. George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5(1):265-272.
40. Waring WS, Adwani SH, Breukels O, et al. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart. 2004;90(2):155-159.
41. Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol. 2001;38(7):1850-1858.
42. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78(11):6858-6862.
43. Nieto FJ, Iribarren C, Gross MD, et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148(1):131-139.
44. Vaccarino V, Krumholz HM. Risk factors for cardiovascular disease: one down, many more to evaluate. Ann Intern Med. 1999;131(1):62-63.
45. Waring WS, McKnight JA, Webb DJ, et al. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia. 2007;50(12):2572-2579.
46. Khan F, George J, Wong K, et al. The association between serum urate levels and arterial stiffness/endothelial function in stroke survivors. Atherosclerosis. 2008;200(2):374-379.
47. Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94(7):932-935.
48. Sakr SA, Abbas TM, Amer MZ, et al. Microvascular angina. The possible role of inflammation, uric acid, and endothelial dysfunction. Int Heart J. 2009;50(4):407-419.
49. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-1225.
50. Jensen-Urstad K, Johansson J, Jensen-Urstad M. Vascular function correlates with risk factors for cardiovascular disease in a healthy population of 35-year-old subjects. J Intern Med. 1997;241(6):507-513.
51. Laclaustra M, Frangi AF, Frangi AG, et al. Association of endothelial function and vascular data with LDL-c and HDL-c in a homogeneous population of middle-aged, healthy military men: evidence for a critical role of optimal lipid levels. Int J Cardiol. 2008;125(3):376-382.
52. Holubkov R, Karas RH, Pepine CJ, et al. Large brachial artery diameter is associated with angiographic coronary artery disease in women. Am Heart J. 2002;143(5):802-807.
53. Yu MA, Sanchez-Lozada LG, Johnson RJ, et al. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234-1242.
54. Hartford M, Wiklund O, Mattsson Hulten L, et al. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med. 2007;262(5):526-536.
55. Albert MA, Glynn RJ, Buring JE, et al. Differential effect of soluble intercellular adhesion molecule-1 on the progression of atherosclerosis as compared to arterial thrombosis: a prospective analysis of the Women's Health Study. Atherosclerosis. 2008;197(1):297-302.
56. Grisar J, Aletaha D, Steiner CW, et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation. 2005;111(2):204-211.
57. Patschan D, Patschan S, Gobe GG, et al. Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. J Am Soc Nephrol. 2007;18(5):1516-1524.
58. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009;120(6):502-509.
59. Harris RA, Nishiyama SK, Wray DW, et al. Ultrasound assessment of flow-mediated dilation. Hypertension. 2010;55(5):1075-1085.
60. Vlachopoulos C, Aznaouridis K, O'Rourke MF, et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31(15):1865-1871.